Clinical Trial Update: Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase II neoadjuvant study of RAD001 (everolimus) in men with intermediate or high-risk prostate cancer. The current status of the trial is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• RAD001 (Everolimus) (everolimus)

Snippet

Sponsor: Sheba Medical Center | Conditions: Prostate Cancer | Phase 2 | Status: UNKNOWN